Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Sponsor: Boryung Pharmaceutical Co., Ltd
Summary
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Official title: A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
OBSERVATIONAL
Enrollment
10000
Start Date
2024-09-30
Completion Date
2027-03
Last Updated
2024-10-18
Healthy Volunteers
No
Conditions
Locations (2)
Andong Hospital
Andong, Gyeongsangbuk-do, South Korea
Konkuk University medical center
Seoul, South Korea